Icon Plc (NASDAQ:ICLR) Given Average Recommendation of “Hold” by Brokerages

Posted by on May 24th, 2026

Shares of Icon Plc (NASDAQ:ICLR – Get Free Report) have earned a consensus rating of “Hold” from the seventeen brokerages that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $145.6667.

A number of research analysts have weighed in on ICLR shares. Weiss Ratings lowered Icon from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Jefferies Financial Group set a $135.00 price objective on Icon and gave the company a “buy” rating in a report on Monday, February 23rd. Robert W. Baird set a $119.00 price objective on Icon in a report on Friday, February 13th. TD Cowen upgraded Icon from a “hold” rating to a “buy” rating and decreased their price objective for the company from $183.00 to $120.00 in a report on Wednesday, February 18th. Finally, Barclays decreased their price objective on Icon from $200.00 to $120.00 and set an “equal weight” rating on the stock in a report on Monday, March 9th.

Get Our Latest Stock Report on ICLR

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC raised its holdings in shares of Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after acquiring an additional 56 shares during the period. Geneos Wealth Management Inc. raised its holdings in shares of Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the period. New Wave Wealth Advisors LLC raised its holdings in shares of Icon by 5.1% during the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after acquiring an additional 72 shares during the period. Signaturefd LLC raised its holdings in shares of Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after acquiring an additional 72 shares during the period. Finally, Janney Montgomery Scott LLC raised its holdings in shares of Icon by 0.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock worth $4,363,000 after acquiring an additional 93 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Trading Up 0.2%

Shares of ICLR stock opened at $116.78 on Friday. The stock’s fifty day moving average is $110.44 and its two-hundred day moving average is $142.81. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The firm has a market capitalization of $9.43 billion, a P/E ratio of 15.80, a PEG ratio of 3.05 and a beta of 1.23. Icon has a fifty-two week low of $66.57 and a fifty-two week high of $211.00.

Icon Company Profile

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

Featured Stories

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.